The Restasis Eye Drop Patent Antitrust Class Action is a major antitrust lawsuit against Allergan, the pharmaceutical company that manufactured and aggressively protected the patent for Restasis, a widely prescribed dry eye medication. Allergan used fraudulent tactics—including false patent filings, misleading FDA submissions, and what courts later called a “commercial rental of a tribe’s sovereign immunity”—to keep generic competitors off the market for years longer than legally permissible. The litigation resulted in two substantial settlements totaling over $81 million: a $51.25 million direct purchaser settlement and a $29.99 million end-payor settlement approved in August 2022. What makes this case notable is not just the settlement amounts, but the methods Allergan allegedly used to extend its monopoly.
Instead of competing on innovation or price, the company repeatedly filed sham citizen petitions with the FDA to delay generic approvals, misrepresented clinical trial data to support false superiority claims, and in one of the most unusual moves in pharmaceutical litigation, transferred its patents to the Saint Regis Mohawk Tribe to invoke sovereign immunity—a tactic the U.S. Department of Justice publicly criticized and courts ultimately rejected. For consumers and their insurers, this case illustrates how patent manipulation can inflate drug prices. Restasis, which costs as little as $1 per dose to manufacture, was priced at significantly higher levels while Allergan’s patent barriers kept generic alternatives unavailable. Anyone who purchased or whose insurance paid for Restasis between the relevant class period dates may be eligible for compensation.
Table of Contents
- How Did Allergan Fraudulently Extend the Restasis Patent?
- What Were the Settlement Amounts and Court Details?
- What Impact Did the Patent Manipulation Have on Restasis Pricing?
- Who Is Eligible for Settlement Compensation?
- What Was the “Tribal Sovereignty” Strategy and Why Did It Fail?
- When Did Generics Finally Reach the Market?
- Broader Lessons from the Restasis Antitrust Case
- Conclusion
How Did Allergan Fraudulently Extend the Restasis Patent?
allergan‘s strategy to maintain exclusivity went beyond standard patent protection—it involved deliberate deception on multiple fronts. The company fraudulently obtained patents from the U.S. Patent & Trademark Office and then fraudulently listed those patents with the FDA, a requirement intended to prevent generic competition during patent protections. More aggressively, Allergan filed repeated sham citizen petitions requesting that the FDA delay generic Restasis approvals, a tactic that forced the agency to take time reviewing petitions the company knew were without merit. One particularly egregious misrepresentation involved clinical trial data.
Allergan claimed that a lower-strength formulation of cyclosporine (Restasis) worked better for dry eye treatment than a higher-strength version—a claim contradicted by the actual clinical evidence. This misrepresentation was designed to prevent competitors from bringing stronger formulations to market while suggesting Allergan’s original product was the superior choice. For patients and insurers, this meant paying premium prices for what the evidence suggested was not the optimal formulation available. The cumulative effect of these tactics was to delay generic competition by years. Pfizer’s generic cyclosporine product (through its InnoPharma subsidiary) was not permitted to enter the market until February 2024 or later, as part of a settlement Allergan eventually negotiated with the patent challenger, long after the original patent should have expired.
What Were the Settlement Amounts and Court Details?
The Restasis antitrust litigation was consolidated into a multidistrict litigation (MDL) in the United States District Court for the Eastern District of New York, case number 1:18-md-02819, presided over by Judge Nina Gershon. The case captured two distinct classes of plaintiffs: direct purchasers (pharmacies, hospitals, and pharmacy benefit managers that directly bought Restasis from Allergan) and end-payors (insurance companies and self-insured employers who ultimately paid for the medication but didn’t purchase it directly). The direct purchaser class received a $51.25 million settlement from Allergan, compensating them for inflated prices paid during the period of patent monopoly protection. The end-payor class settlement of $29.99 million was approved on August 2, 2022, and compensated health insurers and employer-sponsored plans that bore the cost of Restasis while generic alternatives remained unavailable.
Combined, these settlements exceeded $81 million—substantial, though likely a fraction of the total economic harm caused by keeping Restasis prices elevated while excluding generic competition. A critical limitation: settlement amounts are typically distributed across all class members, so individual payouts can be modest, especially for those with smaller claims. Someone whose insurance paid $500 total for Restasis over the class period would receive far less per claim than someone whose insurer paid $5,000 or more. Claims must be filed during specific notice periods, and unclaimed settlement funds may be distributed to cy pres recipients (charities or organizations related to the case’s subject matter) rather than returned to injured consumers.
What Impact Did the Patent Manipulation Have on Restasis Pricing?
Restasis, a cyclosporine ophthalmic emulsion 0.05% prescribed for dry eye disease, became one of the most expensive eye drops available—not because of high manufacturing costs or superior efficacy compared to generics, but because Allergan held exclusive patent protection and actively prevented competition. Industry analysis suggests the drug cost approximately $1 per dose to manufacture, yet pricing for patients and insurers reached far higher levels, sometimes exceeding $3,000 to $5,000 per annual supply depending on dosing frequency. This price differential benefited Allergan enormously. Every year the patent remained protected, the company captured market share from potentially cheaper alternatives.
Once generic cyclosporine became available following Allergan’s settlement with InnoPharma, prices dropped significantly—a pattern that repeats consistently when pharmaceutical monopolies end. Patients on copay structures benefited immediately, but health insurers and self-insured employers that had paid the elevated prices during the monopoly period had no recourse except through the antitrust settlements. A key limitation: the settlements do not affect Allergan’s ability to continue selling Restasis at whatever price the market will bear. The company is not required to discount prices retroactively for non-settling customers, nor are damages awarded directly to individual patients. Insurance companies and pharmacy benefit managers recover, but individual out-of-pocket payers during the monopoly period typically cannot recover separately unless they happen to be named class members.
Who Is Eligible for Settlement Compensation?
Eligibility depends on which class you fall into and when you purchased or paid for Restasis. The direct purchaser class includes entities that directly purchased Restasis from Allergan during the class period—primarily pharmacies, hospital pharmacies, long-term care facilities, and pharmacy benefit managers. The end-payor class includes health insurers, employer-sponsored health plans, health maintenance organizations, and self-insured employers that paid for Restasis claims submitted by covered individuals during the relevant timeframe. Individual consumers who paid out-of-pocket for Restasis prescriptions face a more ambiguous eligibility situation.
Some settlements may include provisions for individual consumers, while others focus exclusively on institutional purchasers. To determine if you are eligible, you must identify which settlement applies to your situation (direct purchaser or end-payor) and obtain documentation of Restasis purchases or payments during the specified class period. Claims must be submitted with proof of purchase—a prescription receipt, insurance explanation of benefits, or pharmacy record—and deadlines for filing typically run 12 to 24 months from the settlement approval date. A significant trade-off: while the settlements provide a legal remedy for antitrust harm, individual claim payments are often modest because the settlement funds are divided among potentially hundreds of thousands of claimants. If you purchased only one or two bottles of Restasis out-of-pocket, your individual recovery might be $10 to $50, whereas institutional purchasers with large aggregate claims could receive substantial compensation.
What Was the “Tribal Sovereignty” Strategy and Why Did It Fail?
In what legal observers described as an unprecedented and aggressive maneuver, Allergan attempted to transfer its Restasis patents to the Saint Regis Mohawk Tribe in order to invoke sovereign immunity—the legal doctrine that shields Native American tribes from certain lawsuits. The theory was that by vesting ownership in a tribal entity, Allergan could argue it was no longer the target of litigation and claims against the tribe should be dismissed. The U.S. Department of Justice publicly criticized the strategy as “commercial rental of a tribe’s sovereign immunity,” underscoring the view that this was a manipulative use of tribal status rather than a genuine business arrangement. Courts rejected the sovereign immunity defense.
Multiple judges found that while the Saint Regis Mohawk Tribe did hold legal title to the patents, the arrangement was a transparent attempt to shield Allergan from liability and that Allergan retained effective control over the patents and continued to benefit from them. The transfer did not occur in a genuine commercial context or as part of a real tribal enterprise; instead, it was structured specifically to exploit sovereign immunity. This ruling clarified an important legal boundary: Native American tribes’ sovereign immunity cannot be weaponized as a liability shield for corporate defendants using paper transfers. A critical warning: while this specific gambit failed, it signals the extreme lengths pharmaceutical companies may pursue to maintain monopolistic control. For consumers and policymakers, the case demonstrates that patent protections alone do not justify using fraudulent methods, sham petitions, or exotic legal theories to delay generic competition. The courts’ rejection of the sovereign immunity defense also protects the integrity of tribal sovereignty itself by preventing it from becoming a tool for corporate rent-seeking.
When Did Generics Finally Reach the Market?
As part of a settlement agreement between Allergan and Pfizer’s generic manufacturer InnoPharma, Allergan agreed to allow generic cyclosporine ophthalmic emulsion to enter the market in February 2024 or earlier under certain conditions. This settlement resolved patent litigation between the two companies and effectively ended Allergan’s ability to block generic competition through further patent claims or litigation delays. The generic entry date marked the practical end of Restasis’s market exclusivity, even though Allergan retained the right to continue selling its branded Restasis product.
Once generic cyclosporine became available, prices for the medication fell sharply. Consumers, pharmacies, and insurers suddenly had alternatives, competition drove down costs, and the artificial price premium that characterized the monopoly period evaporated. For patients with new prescriptions after the generic launch, the benefit was immediate and substantial. For those who had paid inflated prices during the pre-generic monopoly period, the antitrust settlements provided the primary financial remedy.
Broader Lessons from the Restasis Antitrust Case
The Restasis litigation is frequently cited as a cautionary tale about how patent protections can be abused to maintain monopolistic pricing long after the original innovation’s merits have been established. Unlike cases where patent extensions reflect genuine new clinical discoveries or formulations, the Allergan case involved maintaining the same low-strength cyclosporine formulation while using fraud, misleading FDA submissions, and baseless citizen petitions to lock competitors out. It illustrates why antitrust law, FDA oversight, and patent law must work in concert to prevent such abuses.
Looking forward, the case has influenced regulatory and legal scrutiny of pharmaceutical companies’ delay tactics. Patent settlement agreements between brand manufacturers and generic competitors now face greater scrutiny to ensure they are not designed to unreasonably delay generic entry. The Federal Trade Commission has increased focus on “pay-for-delay” settlements and other mechanisms that use legal procedures to suppress competition. For future patients and consumers, the Restasis case serves as a reminder that even well-established medications can become subjects of monopolistic practices—and that settlements and antitrust actions, while slower than competitive markets, do eventually provide financial recourse.
Conclusion
The Restasis Eye Drop Patent Antitrust Class Action resulted in total settlements exceeding $81 million compensating direct purchasers and end-payors harmed by Allergan’s fraudulent patent practices, misleading clinical trial representations, and abuse of administrative procedures. The case demonstrates how pharmaceutical companies can abuse patent systems and FDA processes to maintain monopolistic pricing, keeping generic alternatives unavailable for years beyond what patent law or public health would justify.
If you purchased Restasis or your insurance paid for it during the class period (generally between 2007 and the generic launch in 2024), you may be eligible for settlement compensation. To pursue a claim, obtain documentation of your Restasis purchases or payments and submit a claim form within the specified deadline. The settlements provide important financial remedies, though individual claim amounts may be modest depending on your aggregate purchases during the monopoly period.